Seelos Therapeutics (Seelos Therapeutics) EV-to-EBITDA : -0.41 (As of Apr. 29, 2024)

View and export this data going back to 1999. Start your Free Trial

What is Seelos Therapeutics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Seelos Therapeutics's enterprise value is $15.21 Mil. Seelos Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-36.94 Mil. Therefore, Seelos Therapeutics's EV-to-EBITDA for today is -0.41.

The historical rank and industry rank for Seelos Therapeutics's EV-to-EBITDA or its related term are showing as below:

SEEL' s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.02 Med: -0.69 Max: -0.22
Current: -0.41

During the past 13 years, the highest EV-to-EBITDA of Seelos Therapeutics was -0.22. The lowest was -10.02. And the median was -0.69.

SEEL's EV-to-EBITDA is ranked worse than
100% of 472 companies
in the Biotechnology industry
Industry Median: 9.095 vs SEEL: -0.41

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-29), Seelos Therapeutics's stock price is $0.291. Seelos Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-13.730. Therefore, Seelos Therapeutics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Seelos Therapeutics EV-to-EBITDA Historical Data

The historical data trend for Seelos Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seelos Therapeutics EV-to-EBITDA Chart

Seelos Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBITDA

Get a 7-Day Free Trial

-0.51

-4.24

-1.74

-1.05

-0.66

Seelos Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBITDA	Get a 7-Day Free Trial															-1.05	-1.21	-1.97	-0.87	-0.66

Competitive Comparison of Seelos Therapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Seelos Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Seelos Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seelos Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Seelos Therapeutics's EV-to-EBITDA falls into.

Seelos Therapeutics EV-to-EBITDA Calculation

Seelos Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	15.213	/	-36.942
	=	-0.41

Seelos Therapeutics's current Enterprise Value is $15.21 Mil.
Seelos Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.94 Mil.

Seelos Therapeutics (NAS:SEEL) EV-to-EBITDA Explanation

Seelos Therapeutics's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.291	/	-13.730
	=	At Loss

Seelos Therapeutics's share price for today is $0.291.
Seelos Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.730.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Seelos Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Seelos Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Seelos Therapeutics (Seelos Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seelos Therapeutics Inc (NAS:SEEL) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

300 Park Avenue, 2nd Floor, New York, NY, USA, 10022

Website

https://www.seelostherapeutics.com

Seelos Therapeutics Inc is a clinical-stage biotechnology company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders.

Executives

Raj Mehra	director, officer: See Remarks	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Michael Joseph Golembiewski	officer: Chief Financial Officer	7 TURTLE CT, FLEMINGTON NJ 08822
Daniel J. O'connor	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Margaret Dalesandro	director	ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Judith Dunn	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Brian Lian	director	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Robin L Smith	director	C/O PHASE III MEDICAL, INC., 330 SOUTH SERVICE ROAD, SUITE 120, MELVILLE NY 11747
Neil Morton	officer: SVP, Chief Business Officer	C/O APRICUS BIOSCIENCES, INC., 11975 EL CAMINO REAL, SUITE 300, SAN DIEGO CA 92130
Richard W Pascoe	director, officer: CEO & Secretary	C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Alexander J Denner	10 percent owner	C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Sarissa Capital Management Lp	10 percent owner	660 STEAMBOAT ROAD, GREENWICH CT 06830
Sarissa Capital Domestic Fund Lp	10 percent owner	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830